Given previous reports of metabolic changes in breast tumors following Her2 downregulation, we proposed to capture the balance between glycolysis and mitochondrial metabolism and demonstrate how the balance of both could shift throughout a tumor’s dormancy cycle12,26–29. The gene discussed is ERBB2; the disease is neoplasm.